Skip to main content

Table 1 Descriptive composition of included subjects in terms of baseline amyloid status, APOE-ε4 carriership, sex, age, and annualized accumulation rates in DVR and SUVR

From: Strategies to reduce sample sizes in Alzheimer’s disease primary and secondary prevention trials using longitudinal amyloid PET imaging

  Whole cohort Low burden group (CL ≤ 20.1) Intermediate burden group (20.1 < CL ≤ 49.4) High burden group (CL > 49.4)
All APOE-ε4 non-carriers APOE-ε4 carriers All APOE-ε4 non-carriers APOE-ε4 carriers All APOE-ε4 non-carriers APOE-ε4 carriers All APOE-ε4 non-carriers APOE-ε4 carriers
Number of subjects (%) 237 (100) 159 (67.1) 78 (32.9) 194 (81.8) 146 (75.2) 48 (24.8) 20 (8.44) 5 (25.0) 15 (75.0) 23 (9.70) 8 (34.8) 15 (65.2)
Number of women (%) 154 (65.0) 100 (62.9) 54 (69.2) 129 (66.5) 95 (65.1) 34 (70.8) 13 (65.0) 1 (20.0) 12 (80.0) 12 (52.2) 4 (50.0) 8 (53.3)
Age, years 65.3 ± 9.4 65.8 ± 9.5 64.5 ± 9.2 64.4 ± 9.6 65.3 ± 9.7 61.7 ± 9.2 67.6 ± 7.4 67.7 ± 3.9 67.6 ± 8.3 71.1 ± 6.6 72.4 ± 7.0 70.3 ± 6.5
SUVR (cortical composite)
 Baseline (IQR) 1.08 (1.05–1.14) 1.07 (1.05–1.12) 1.15 (1.05–1.44) 1.07 (1.04–1.11) 1.07 (1.04–1.10) 1.07 (1.04–1.14) 1.40 (1.29–1.45) 1.38 (1.30–1.47) 1.41 (1.28–1.45) 1.73 (1.61–1.91) 1.79 (1.59–1.91) 1.72 (1.61–1.91)
 Annual % change 1.06 (1.30) 0.77 (1.08) 1.63 (1.53) 0.80 (1.18) 0.69 (0.99) 1.15 (1.56) 2.83 (0.93) 2.81 (0.69) 2.84 (1.02) 1.77 (1.18) 2.37 (1.34) 1.98 (1.07)
 Effect size 0.76 0.69 1.10 0.69 0.63 0.72 3.54 4.75 3.00 1.58 1.05 1.89
 Number of accumulators (%) [CUs TRT] 45 (23.6) 25 (15.7) 31 (39.7) 27 (13.9) 17 (11.6) 10 (20.8) 17 (85.0) 5 (100.0) 12 (80.0) 12 (52.2) 3 (37.5) 9 (60.0)
 Number of accumulators (%) [ALL TRT] 20 (8.4) 5 (3.1) 15 (19.2) 10 (5.2) 3 (2.1) 7 (14.6) 7 (35.0) 1 (20.0) 6 (40.0) 3 (13.0) 1 (12.5) 2 (13.3)
SUVR (early composite)
 Baseline (IQR) 1.16 (1.08–1.23) 1.14 (1.11–1.18) 1.22 (1.13–1.54) 1.14 (1.11–1.18) 1.14 (1.11–1.17) 1.15 (1.11–1.20) 1.50 (1.41–1.54) 1.50 (1.42–1.53) 1.50 (1.38–1.55) 1.79 (1.73–1.99) 1.89 (1.78–2.03) 1.79 (1.71–1.98)
 Annual % change 1.25 (1.26) 0.99 (1.08) 1.75 (1.44) 1.02 (1.16) 0.91 (1.03) 1.34 (1.44) 2.87 (1.02) 2.74 (0.90) 2.90 (1.08) 1.74 (1.13) 1.36 (1.17) 1.94 (1.09)
 Effect size 0.94 0.86 1.20 0.86 0.87 0.94 3.23 3.41 3.00 1.55 1.18 1.84
DVR (cortical composite)
 Baseline (IQR) 1.05 (1.02–1.10) 1.04 (1.01–1.07) 1.10 (1.03–1.30) 1.04 (1.01–1.06) 1.04 (1.01–1.06) 1.04 (1.02–1.09) 1.26 (1.21–1.30) 1.29 (1.21–1.34) 1.25 (1.20–1.30) 1.54 (1.43–1.69) 1.59 (1.44–1.71) 1.53 (1.43–1.69)
 Annual % change 0.75 (1.11) 0.50 (0.91) 1.25 (1.30) 0.49 (0.96) 0.40 (0.82) 0.75 (1.29) 2.34 (0.72) 2.53 (0.43) 2.34 (0.80) 1.55 (0.93) 1.16 (1.07) 1.76 (0.80)
 Effect size 0.69 0.54 1.00 0.48 0.50 0.57 3.75 7.11 3.22 1.86 1.06 2.25
 Number of accumulators (%) [CUs TRT] 81 (34.2) 39 (24.5) 42 (53.8) 44 (22.7) 29 (19.9) 15 (31.3) 20 (100.0) 5 (100.0) 15 (100.0) 17 (73.9) 5 (62.5) 12 (80.0)
 Number of accumulators (%) [ALL TRT] 33 (13.9) 11 (6.9) 22 (28.2) 13 (6.7) 6 (4.1) 7 (14.6) 13 (65.0) 4 (80.0) 9 (60.0) 7 (30.4) 1 (12.5) 6 (40.0)
DVR (early composite)
 Baseline (IQR) 1.11 (1.08–1.17) 1.10 (1.07–1.13) 1.16 (1.09–1.38) 1.09 (1.07–1.12) 1.09 (1.07–1.12) 1.10 (1.07–1.14) 1.34 (1.31–1.39) 1.39 (1.32–1.41) 1.34 (1.27–1.38) 1.66 (1.54–1.77) 1.72 (1.56–1.82) 1.59 (1.51–1.70)
 Annual % change 0.94 (1.08) 0.72 (0.94) 1.34 (1.22) 0.71 (0.97) 0.63 (0.87) 0.94 (1.19) 2.49 (0.76) 2.55 (0.71) 2.47 (0.80) 1.50 (0.89) 1.15 (0.96) 1.68 (0.83)
    Effect size 0.78 0.72 1.12 0.72 0.70 0.76 3.67 3.89 3.43 1.71 1.19 2.17
  1. Values are described as mean ± standard deviation unless otherwise indicated. CU stands for cognitively unimpaired